Jian Sun
Corporate Officer/Principal bei Lianyuangang Chia Tai Tianqing Medicine Co., Ltd.
Profil
Jian Sun is currently the General Manager at Lianyuangang Chia Tai Tianqing Medicine Co., Ltd.
Prior to this, he was the President at Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Aktive Positionen von Jian Sun
| Unternehmen | Position | Beginn |
|---|---|---|
| Lianyuangang Chia Tai Tianqing Medicine Co., Ltd. | Corporate Officer/Principal | 19.08.2011 |
Ehemalige bekannte Positionen von Jian Sun
| Unternehmen | Position | Ende |
|---|---|---|
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The company was founded in 1969, and the CEO is Kang Xin Yu. | Präsident | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The company was founded in 1969, and the CEO is Kang Xin Yu. | Health Technology |
| Lianyuangang Chia Tai Tianqing Medicine Co., Ltd. |
